The vav proto-oncogene product is a 95 kDa protein predominantly expressed in hematopoietic cells. Vav presents a wide range of functional domains, including structural domains known to be involved in signal transduction. Triggering of various cytokine receptors among which type I interferon receptor induces a rapid and transient tyrosine phosphorylation of p95
Introduction
The Vav proto-oncogene, a 95 kDa protein, was discovered and subsequently cloned by Katzav et al. (1989) . Predominantly expressed in hematopoietic cells (Katzav, 1995), p95 vav is an interesting molecule which presents a wide range of functional domains. These domains include a Leucin zipper-like motif (LZ), a helix ± loop ± helix (HLH) domain at the NH2 terminal region, a cysteine rich and a nuclear translocation domain, suggesting that Vav could exert nuclear functions. p95
vav also contains motifs, such as SH2 and SH3 domains, a pleckstrin homology (PH) domain and a Dbl homology (DH) domain, a common motif in most GEFs for small GTP-binding proteins, indicating that this protein may interact with multiple components of the signaling pathway (Romero and Fischer, 1996) .
The functions of p95
vav in hematopoietic cells are not fully elucidated, however dierent reports indicated that p95 vav might be critical for hematopoiesis, particularly for adult erythropoiesis or myeloid progenitor cell growth in some hematopoietic malignancies (Bustelo et al., 1993; Luger et al., 1996) . Further, experiments of gene disruption suggested that p95
vav has a major role in the antigen receptor-mediated proliferation of T and B lymphoid cells (Wu et al., 1995; Tarakhosky et al., 1995; Zhang et al., 1995; Bustelo and Barbacid, 1992) . Besides, the presence of structural domains known to be involved in tyrosine signal transduction strongly suggests that the protooncogene Vav could be a key signaling transducer in the hematopoietic system. Actually, various hematopoietic growth factors and cytokines have been shown to induce transient tyrosine phosphorylation of the proto-oncogene product (Alai et al., 1992; Matsuguchi et al., 1995; Evans et al., 1993; Miyakawa et al., 1997) ; however whether Vav is absolutely required in biological eects induced by any cytokines remains unclear.
Recently the type I interferon, IFN-a, has been shown to phosphorylate p95 vav in human hematopoetic cell lines of B-cell, T-cell and promyelocytic origin . The type I interferons, which consist of several dierent biologically active subtypes of IFN-a, of one IFNb and IFN-o, bind to a common receptor. The functional type I IFN receptor is composed of two distinct subunits, the a chain or IFNAR1 (UzeÂ et al., 1990 ) and the b chain or IFNAR2, of which two transmembrane forms (long and short forms) have been identi®ed, resulting from alternative splicing of the same gene (Novick et al., 1994; Domanski et al., 1995) ; IFN-a treatment of human cells induces tyrosine phosphorylation of both subunits and activation of the protein tyrosine kinases, Tyk2 and JAK1, which are constitutively associated with IFNAR1 and IFNAR2, respectively. Activation of Tyk2 and JAK1 engages multiple proteins to transduce type I interferon signals, including signal transducers and activators of transcription (Stat) proteins, i.e. Stat-1, Stat-2 and Stat-3 components of the transcription factor complex ISGF-3 that translocate to the nucleus and interact with the IRSE sequence on the cognate genes. This leads to transcriptional activation and to the subsequent biological activities attributable to type I IFNs (Williams and Haque, 1997) .
The type I IFNs are a group of naturally occurring inducible proteins which exhibit pleiotropic biological eects that include antiviral and antiproliferative activities, in normal and neoplastic cells, in vitro and in vivo (Gutterman, 1994) . Consequently IFN, mainly IFN-a has emerged as a treatment in viral and hematological malignant diseases, and is applied in major clinical trials including trials with chronic myelogenous leukemia Ph+ (CML) (Talpaz et al., 1986) and other chronic myeloproliferative disorders (CMPDs) (Sacchi, 1995) . In particular, IFN-a has been shown to control thrombocytosis in CMPDs featured by an abnormal expansion of the megakaryocytic population (Sacchi, 1995) ; this observation is in agreement with the capacity of IFN-a to inhibit human megakaryopoiesis derived from normal or pathological bone marrow (Carlo-Stella et al., 1987) . The analysis of the mechanisms of signal transduction of cytokines in megakaryocytes is technically dicult, due to the rarity of these cells in bone marrow. Hence in vitro models, i.e. human megakaryoblastic cell lines, provide a valuable model for study.
In previous studies we showed the antiproliferative eects of IFN-a on human cells with megakaryotic features, the Dami cell line, and we characterized speci®c functional receptors for IFN-a in these cells (MartyreÂ and Wietzerbin, 1994) . Although the activation of the Jak ± Stat pathway may be crucial in mediating IFN biological eects, it cannot be ruled out that alternative pathways may be involved, as suggested by the IFN-ainduced tyrosine phosphorylation of a protein such as the Vav proto-oncogene. The experiments presented herein examine the role of Vav during the stimulation of the type I IFN receptor in megakaryocytic cells. Our data show that p95
vav associates with the a and b chains of the type I IFN receptor and that after IFN-a treatment the phosphorylated form of p95 vav translocates to the nucleus. Moreover, our results strongly suggest that p95 vav contributes to the antiproliferative eects of IFN-a in megakaryocytic cell lines.
Results

Tyrosine phosphorylation of p95
vav by type I IFN treatment
To determine whether p95
vav is phosphorylated in Dami and UT7 cells after IFN-a/b stimulation, the cells were serum starved for 24 h prior to the experiment and further treated with 1000 U/mL IFN-a2a or b for dierent periods of time. Then cell lysates were immunoprecipitated with either control non immune rabbit serum or a rabbit polyclonal antibody against p95 vav prior to SDS ± PAGE analysis and anti-phosphotyrosine immunoblotting. Since Stat2 has been shown to be activated in IFN-a signaling, Dami cell lysates were also immunoprecipitated with a rabbit polyclonal antibody against Stat2 to assess the reliability of the stimulation by IFN-a2a.
In both Dami and UT7 cell lines a base-line of phosphorylation of p95 vav was detectable prior to IFN-a stimulation (Figure 1a,b) . IFN-a treatment increased the tyrosine phosphorylation of p95 vav after 15 min. Though declining, the signal remained slightly detectable after 2 h of IFN-a exposure. Reprobing of the same blot with the p95 vav polyclonal antibody showed that equal amounts of immunoprecipitated p95
vav were loaded in all lanes (Figure 1a) .
In Dami cells Stat2 was also tyrosine phosphorylated by IFN-a treatment, but in a dierent time-dependent manner than p95 vav (Figure 1a) . Actually, Stat2 was tyrosine phosphorylated after 5 min of treatment. The signal remained even and was still detectable after 2 h of IFN-a exposure. Reprobing of the same blot with an anti-Stat2 polyclonal antibody showed that equal amounts of Stat2 immunoprecipitates were present in untreated and treated cells (Figure 1a) .
Tyrosine phosphorylation of p95 vav was also observed when cells were treated with IFN-b (Figure 1c) .
Interaction of p95
vav with type I interferon receptor chains in megakaryocytic cells
To determine whether p95
vav interacts with the type I interferon receptor and whether such an interaction is modulated by IFN-a or IFN-b stimulation, the cells treated with either type I IFN (1000 U/ml, 30 min) were lysed under mild conditions in Brij detergent; the cell lysates were immunoprecipitated with rabbit polyclonal antibodies against IFNAR1 (a subunit) or vav and IFNAR1 or IFNAR2. It is noteworthy that the increase of this association of p95 vav with type I IFN receptor chains, and particularly with IFNAR2, seemed higher after IFN-b treatment.
To further con®rm these results, lysates were immunoprecipitated with anti-p95 vav polyclonal antibody and immunoblotted with anti-IFNAR1 or -IFNAR2 polyclonal antibodies. p95
vav was co-immunoprecipitated with the type I IFN receptor in untreated cells; this co-precipitation was increased under IFN type I stimulation ( Figure 2c ). As previously, the association between p95
vav and both chains of the type I IFN receptor, particularly IFNAR2, appeared to be higher in IFN-b treated cells than in IFN-a treated cells, though it is quite dicult to conclude. However, similar protein amounts have been immunoprecipitated with the same p95 vav antibody (Figure 2c ), the yield of immunoprecipitation supposed to be identical; then the totality of the immunoprecipitates have been loaded and immunoblotted with the same anti-IFNAR2. Thus, these results strongly suggest that IFN-b might be a stronger inducer of the receptor-p95 vav interaction.
Nuclear translocation of tyrosine phosphorylated p95
vav under IFN-a stimulation
Reports (Clevenger et al., 1995; Romero et al., 1998) and cDNA analyses have suggested that p95 vav could be involved in nuclear functions. Besides, the nuclear protein Ku-70 has been shown to interact with p95 vav (Romero and Fischer, 1996) . To evaluate the potential implication of the association Vav/Ku-70 in IFN-a signaling, in megakaryocytic cells, lysates from treated and non treated Dami cells were immunoprecipitated with an anti-Vav polyclonal antibody and subsequently immunoblotted with an antibody directed against Ku-70. In the absence of stimulation p95
vav was associated with Ku-70 in Dami cells; this interaction was increased after IFN-a treatment, thus suggesting a constitutive nuclear localization of p95 vav and its further nuclear translocation after IFN stimulation (Figure 3 ).
To further demonstrate the nuclear translocation of the activated p95 vav under type I IFN stimulation, nuclear extracts were prepared from cells untreated or treated with IFN-a for dierent periods of time; these extracts were immunoprecipitated with an anti-p95 vav antibody. The blots were developed with an antiphosphotyrosine monoclonal antibody. Figure 4a indicates that phosphorylated p95 vav appeared in nuclear extracts from Dami cells after 15 min up to 1 h of stimulation with 1000 U/ml IFN-a. p95
vav was further quanti®ed in these nuclear extracts immunoprecipitated and subsequently immunoblotted with the anti-p95 vav antibody, by phosphorimager analysis after incubation with 125 I-protein A. The data indicated that a moderated but signi®cant increase in intranuclear p95
vav occurred under IFN stimulation. In Figure 4b the results of phosphorimager quanti®cation show that this increase in intranuclear p95
vav correlates with the kinetics of intranuclear phosphorylated p95
vav detection.
The same nuclear extracts were immunoprecipitated with the anti-Stat2 polyclonal antibody. Then the blots were probed with the same anti-Stat2 antibody. Immunoblot analysis revealed that, subsequent to IFN-a stimulation, Stat2 was translocated into the Dami cell nucleus. However the nuclear translocation kinetics of p95 vav and Stat2 were dierent; Stat2 was translocated into the nucleus after 5 min of IFN stimulation up to 2 h, whereas the phosphorylated form of p95 vav was detected in the nucleus between 15 ± 60 min after stimulation (Figure 4a ). To determine the biological signi®cance of p95 vav in the response to IFN-a, Dami cells were exposed to sense (S), antisense (AS) or scrambled (SCR) sequences of non modi®ed Vav oligodeoxynucleotides (ODN) as described in experimental procedures. The expression of p95
vav was studied at the protein level 36 h after the initial addition of ODN. As shown in Figure 5a , the expression of p95 vav was signi®cantly reduced in AS-ODN treated cells while incubation with control ODN (S or SCR) had no signi®cant eect on the expression level of p95 vav . In parallel, exponentially growing Dami cells were exposed to IFN-a (1000 U/ml) 36 h after the initial oligonucleotides exposure. The growth inhibitory eect of IFN-a was then evaluated by counting the cells at day 2 ± 4 after IFN stimulation. The viability of treated cells, assessed by trypan blue exclusion ranged from 90 ± 95%. In control IFN-treated Dami cells proliferation was markedly inhibited by 30 ± 40% at day 3. The growth of cells exposed to sense or scrambled Vav oligonucleotides, prior to IFN treatment was also signi®cantly inhibited at day 3 ( Figure 5b) ; moreover, treatment with S or SCR constructs led to a potentiation of IFN inhibition of proliferation; this was probably due to the addition of oligonucleotides, which may aect the cell physiology by themselves, as suggested by the weak delay of cell proliferation observed in cells exposed to ODN (S, SCR and AS) alone (data not shown). Interestingly, in antisense ODN pretreated cells the growth inhibitory eect of IFN-a decreased. The abrogation of IFN-a antiproliferative eect by antisense Vav oligonucleotides was maximum at day 3 where cell proliferation was inhibited by no more than 10% ( Figure 5b) ; the potentiation of IFN inhibition of proliferation observed in S and SCR treated cells making these results even more signi®cant.
Eects of Vav oligodeoxynucleotides on c-myc expression in IFN-a treated cells
The antiproliferative eect of IFN-a are accompanied by a decreased expression of c-myc (Einat et al., 1985) . To con®rm that p95
vav participate in such antiproliferative eect, we analysed the c-myc protein expression in Dami cells treated with IFN-a, 36 h after the initial ODN exposure. As shown in Figure  5c vav participates in the IFN-a-induced inhibition of cell proliferation.
While only one form of the a-subunit (IFNAR1) of the type I IFN receptor has been identi®ed, two dierent transmembrane forms of the b-subunit can be expressed, the long one IFNAR2c, and the short one IFNAR2b. Interestingly, the available anti-IFNAR2 antibody that we used being directed against intracytoplasmic residues 314 ± 331 that do not present any homology with the intracytoplasmic region of IFNAR2c, our experiments showed the interaction of p95 vav with IFNAR2b. This is important to be noticed since results concerning the respective role of IFNAR2c and IFNAR2b as components of the functional receptor are still controversial. While a number of data strongly suggest that IFNAR2c is required for signaling, the function of IFNAr2b is still unclear. Particularly, functional receptor was reconstituted using either the mutant cell line U5A or L-929 cells. Actually, the expression of IFNAR2c but not of IFNAR2b in U5A, a mutant cell line completely defective in IFNa/b binding and response, reconstituted a receptor that restored IFN binding, activation of the JAK/Stat signaling pathway and antiviral response (Lutfalla et al., 1995) . Similar results were obtained in mouse L-929 cells in which only coexpression of both a chain IFNAR1, and b chain IFNAR2c allowed a full biological response after stimulation with human IFNa (Domanski et al., 1995) . Besides, other data indicated that IFNAR2b is part of the functional type I IFN receptor as demonstrated by the increased response to IFN-a, measured in a ISRE-luciferase reporter assay, in HeLa cells overexpressing IFNAR2b (Cohen et al., 1995) ; such results supporting the evoked potential role of IFNAR2b as a regulator of the IFNa response. Also, it has been reported that some cell lines expressing variant receptors (IFNAR1 plus IFNAR2b) showed a full IFNa response (Colamonici et al., 1994) . Interestingly our results indicate that Vav interacts with IFNAR2b. Moreover, in Dami cells, the type I receptor is functional as both Vav and Stat2 are phosphorylated and translocated into the nucleus after IFN-a ligation and that Dami cell proliferation is inhibited in response to IFN. Thus, our ®ndings strongly suggest that p95 vav associated with IFNAR2b might participate in the response to type I interferon. Nevertheless, the simultaneous expression of IFNAR2c and IFNAR2b in Dami cells cannot be ruled out, inasmuch as it has been determined that both of them are expressed in most cell lines (Domanski et al., 1995) .
Despite IFNs-a and -b utilize a common type I receptor some dierences between IFN-a and -b signaling have been described. Some ®ndings provided evidence of functional dierences between both IFNs at the level of receptor recognition and early signal transduction (Croze et al., 1996; Velasquez et al., 1995) . Recently, Domanski et al. (1998) showed that the signaling speci®city for IFN-a and -b resulted from the utilization of dierent regions of the intracellular domain of the b chain (IFNAR2) by the two ligand subtypes. Moreover, by expression in mutants of IFNAR2, whose extracellular domain has been modi®ed, it has been demonstrated that IFN-a and -b share receptor components but associated in distinct complexes (Lewerenz et al., 1998 ). Our results demonstrate that not only p95
vav forms a complex with both chains of type I IFN receptor but also that, in megakaryocytic cells, the association of Vav with IFNAR2, particularly, is markedly higher after IFN-b treatment than after IFN-a stimulation. These ®ndings are in agreement with the aforementioned reports and suggest that the anity of the interaction between p95
vav and IFNAR2 could be modulated by the ligand, IFN-a or -b. Concerning the IFN-a/b-induced phosphorylation of p95 vav , in contrast to the ®ndings of Uddin et al. (1997) which demonstrated that p95 vav forms a stable complex with the IFN-receptor a chainassociated Tyk-2 kinase in vivo, despite long exposures of the blots we failed to detect such an association. Our attempts were unsuccessful with either a chainassociated Tyk-2 or b-chain-associated Jak1 kinases, both candidates for mediating phosphorylation of Vav, though the anti-IFNAR1 and 2 antibodies that we used were ecient in immunoprecipitating Tyk2 and JAK1 respectively, as we probed for these kinases in corresponding immunoprecipitates. A low stoichiometry of such associations and/or the speci®city of the antibodies used could account for this failure, in spite of the high number of cells used to immunoprecipitate p95 vav protein. Previously known as a cytoplasmic protein (Hu et al., 1993) , the functions of Vav in cell signaling are not clear though its implication in Ras ± GEF activity has been well documented (Adams et al., 1992; Clevenger et al., 1995) . Besides, though p95 vav contains two nuclear translocation sequences and regions potentially implied in protein-DNA interactions, there is no evidence so far that p95 vav binds to DNA. The recent ®ndings of an interaction of Vav with some nuclear proteins suggest a potential involvement of Vav in the regulation of transcriptional factors and/or transcription regulator proteins (Romero and Fischer, 1996) . These identi®ed proteins include the ubiquitous nuclear DNA-binding protein KU-70 . This cell cycle dependent nuclear protein which associates with the KU-80 protein to form an heteromeric complex, is the regulatory subunit of the nuclear DNA-dependent protein kinase. The DNAdependent protein kinase phosphorylates substrates in vitro, including KU-70 and KU-80, p53 and transcription factors such as SP1, c-jun, c-fos and c-myc (Reeves et al., 1994) . Most of these molecules are involved in the regulation of cell proliferation. Interestingly, the cmyc gene is a key target whose expression is selectively suppressed by IFNs (Einat et al., 1985) . Thus, in the current study, we sought to determine whether p95 vav was coimmunoprecipitated with KU-70. Indeed, previous studies have shown that Vav is translocated to nucleus during erythropoietin (Epo) or prolactin (Clevenger et al., 1995) stimulation. Immunoblotting experiments with nuclear extracts allowed us to establish that it is the phosphorylated form of p95 vav which is translocated to nucleus after IFN-a stimulation and that the total amount of nuclear Vav increases following this stimulation. Moreover, it appeared that the kinetics of appearance of phosphorylated Vav in the nucleus and the kinetics of increase of the association p95 vav /KU-70, were very similar thus suggesting that subsequently to IFN-a stimulation, phosphorylated p95
vav is, at least partly, translocated to the nucleus where it associates with KU-70. Interestingly, the translocation of phosphorylated p95
vav to nucleus occurred after its dissociation from actin (data not shown).
Although the Jak/Stat pathway have been extensively documented (Darnell et al., 1994) , the mechanisms by which type I IFNs induce their eects are not thoroughly understood so far. In our study, it is noteworthy that the kinetics of the nuclear translocation of phosphorylated Vav was dierent from that of the nuclear translocation of Stat2. Besides, though the involvement of second messenger molecules is not absolutely required, evidence supports the activation of second-message pathways which may contribute to the biologic eects of IFNs (Williams and Haque, 1997). Thus, the IFN-induced biological activities are mediated through an apparent complex network of interactions and the existence of additional members in IFN signaling could not be ruled out. The data presented herein suggest that p95
vav could participate in cell signaling by type I IFNs and might provide an alternative link between the type I IFN receptor and the nuclear events which regulate IFN-induced gene expression and IFN-induced biological eects. To test this hypothesis Dami cells were exposed to Vav non modi®ed ODN and treated or not with IFN-a. Lysates were analysed for Vav and c-myc expression. In parallel experiments, the response to IFN-a antiproliferative eect was examined in cells treated in the same conditions. These experiments revealed that Vav protein was greatly diminished only in antisensetreated cells and that, when cells were treated with IFN-a during the time that Vav is absent, c-myc expression remained high while the inhibition of Dami cell proliferation was markedly suppressed. These results are particularly relevant in supporting the hypothesized role of Vav in the antiproliferative eect of IFN-a in Dami cells even though if, with regard to such an hypothesis, the rather rapid`regain' of IFN inhibition in AS-treated cells could appear somewhat intriguing. A plausible interpretation of these data is that p95 vav , in mediating IFN antiproliferative response, probably contributes to an alternative pathway that results in enhanced IFN antiproliferative eects; nevertheless, this interacting pathway may be sustained by a major signaling pathway leading to the complete response to IFN. Recent studies using Vav anti-sense approach showed that p95 vav is involved in the prolactin-driven proliferation of the rat T lymphoid cell line Nb2 (Clevenger et al., 1995) . Besides, using a similar anti-sense methodology, p95 vav has been shown crucial for erythroid lineage commitment and growth from human progenitor cells stimulated with Epo, one of the most critical cytokines that regulate erythropoiesis (Luger et al., 1996) ; these ®ndings are consistent with the fact that p95
vav is phosphorylated in response to prolactin and Epo (Clevenger et al., 1995; Luger et al., 1996; Miura et al., 1994) . Together with these data, our results substantiate the role of p95 vav in cell proliferative responses; even though Vav probably acts through dierent signaling mechanisms as far as cell proliferation or inhibition of cell proliferation are concerned. Actually, it should be kept in mind that, in hematopoietic cells, p95
vav can interact with dierent proteins through a wide array of domains. Thus p95 vav could serve as a`hook' in various signaling transduction pathways; the ®nal biological eect resulting from the speci®city of the combinative association of these dierent proteins.
In conclusion, the data of the present study provide important information on the involvement of Vav, which is unique in hematopoietic cells, in type I IFN signaling. Actually, our results showing the association of p95
vav with a and b chains of the type I IFN receptor, the translocation to nucleus of the Vav phosphorylated form during IFN stimulation, and its contribution to the antiproliferative eect of IFN, strongly suggest that Vav could be part of additional mechanisms in IFN-a signaling pathway.
Materials and methods
Cell lines
The human megakaryoblastic Dami cells originally established by Greenberg et al. (1988) were grown in Iscove's modi®ed Dulbecco's medium (IMDM) (Gibco-BRL, Cergy Pontoise, France) supplemented with 10% horse serum (Gibco-BRL), and antibiotics.
UT-7 cells established from the bone marrow of a patient with a megakaryoblastic leukemia (Komatsu et al., 1991) were maintained in a-modi®ed Eagle medium (a-MEM) with 10% fetal calf serum (Gibco-BRL), 2.5 ng/ml human recombinant GM-CSF (speci®c activity 10 8 U/mg, Sandoz) and antibiotics. For experiments, exponentially growing Dami and UT-7 cells were incubated for 24 h in serum depleted medium to avoid the interfering stimulating eects of cytokines present in serum.
Reagents
Human recombinant IFN-a2a (speci®c activity 2.4610 8 units/mg) was a gift from Homann-La Roche (Basel, Switzerland), human recombinant IFN-b (speci®c activity 4610 8 U/mg) was a gift from Ares-Serono (Geneva, Switzerland). Sodium orthovanadate, phenylmeÂ thyl-sulfonyluoride (PMSF), protease inhibitors were obtained from Sigma. The anti-phosphotyrosine monoclonal antibody 4G10 was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). The following polyclonal antibodies raised against: (i) a peptide corresponding to residues 528 ± 541 of human p95
vav , this antibody reacting only with Vav p95 of human, mouse and rat origin; (ii) a peptide corresponding to residues 832 ± 851 of human Stat2 (p113); (iii) a peptide corresponding to amino acid 1 ± 262 of human c-myc; (iv) residues 314 ± 331 and residues 458 ± 557 of the precursor form of the human IFN-a/bR (IFNAR2) and the human IFN-aR (IFNAR1) respectively; (v) and against a peptide corresponding to residues 590 ± 608 of the human KU-70 protein were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Chemiluminescence (ECL) reagents and Hyper®lms were from Amersham (Arlington Heights, IL, USA). Unmodi®ed oligodeoxynucleotides oligomer sequences were purchased from Eurogentec.
Immunoprecipitation
Cells were cultured in serum depleted medium 24 h prior to experiments so as to exclude the interfering stimulation of the cells by cytokines present in the serum; then they were stimulated with the indicated amounts of IFN-a2a or IFN-b for dierent periods of time. After IFN stimulation, the cells were promptly washed in cold PBS and lysed in lysis-buer consisting of 10 mM Tris/HCl pH 7.5, 0.5% Brij 35 solution (Sigma), 200 mM NaCl, 1.5 mM MgCl 2 , 50 mM NaF, 2 mM EDTA, 1 mM (PMSF), 1 mM Sodium orthovanadate, 10 mg/ ml Pepstatin, 10 mg/ml Leupeptin, 10 mg/ml Aprotinin, 10% glycerol at 48C. Nuclear and cytoplasmic extracts were prepared using hypotonic swelling as previously described (Sanceau et al., 1995) .
Cell lysates were precleared with protein A-Sepharose beads (Pharmacia Biotech) for 1 h at 48C, under gentle shaking. Immunoprecipitates were then performed on precleared lysates using the required antibody (2 ± 5 mg). Control immunoprecipitations utilized an isotype-matched control antibody (Sigma), or control non immune serum (Sigma). Antigen-antibody complexes were collected on protein A-Sepharose beads during a 4 h incubation at 48C. After three washes with buer consisting of 100 mM Tris/HCl pH 8.8, 0.5 M KCl, 0.5% Triton X-100, 10 mg/ml Pepstatin, 10 mg/ml Leupeptin, 10 mg/ml Aprotinin, and once in 10 mM Tris/HCl pH 8.8, 10 mg/ml Pepstatin, 10 mg/ml Leupeptin, 10 mg/ml Aprotinin buer, the immunoprecipitates were prepared for electrophoresis. The immunes complexes were resuspended in twofold concentrated Laemmli buer with 2% b-mercaptoethanol and boiled prior to analysis.
Gel electrophoresis and Western blotting
Immunoprecipitates were resolved by preparative sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) on a 8% gel and then transferred onto Protran BA83 Nitrocellulose membrane (Schleicher & Schuel, Dassel, Germany) . Membranes were blocked by incubating in 0.1% Tween 20 PBS buer (TPBS) with 3% BSA or milk, for 2 h. The membranes were rinsed in TPBS, incubated overnight with the required antibody and developed (i) by the enhanced chemiluminescence (ECL) system, according to the manufacturer's instructions (ECL kit, Amersham Corp.); (ii) or by exposure to PhosphorImager (Molecular Dynamics) after incubation with 125 I-protein A (Amersham, 500 000 c.p.m./ml of PBS containing 2% PBS-FV, 0.1% Tween 20). In case of reprobing of the membranes, they were previously stripped of bound antibodies by incubation in a 100 mM 2-mercaptoethanol, 2% sodium dodecyl sulphate, 62.5 mM Tris/HCl pH 6.7 buer, at 508C for 30 min with occasional agitation, and then washed in large volumes of TPBS buer.
Oligodeoxynucleotides
Non modi®ed oligomer sequences (ODN) were used. Oligomer sequences (ODN) corresponding to codon 2-7 of the human proto Vav cDNA sequence were as follows: [5'-TCC CAG TTC CTG TGC CTT-3']-sense; [5'-AAG GCA CAG GAA CTG GGA-3']-antisense and [5'-AGC TCG AAA GAC AGG GGA-3']-scrambled sequences (Luger et al., 1996) .
Oligomer exposure and cell culture
Dami cells were exposed to oligodeoxynucleotides redissolved in Iscove's modi®ed Dulbecco's medium according to the following procedure: Dami cells (2.5610 5 cells/ml) were incubated in IMDM; ODN (100 mg/2.5610 4 cells) were added at time 0 and 18 h later; 50% of the initial dose was added 36 h after the ®rst addition, just before IFN-a2a stimulation (1000 U/ml). Control cultures contained cells treated in an identical manner but without exposure to ODN. p95 vav expression was examined by immunoblotting 36 h after the initial oligomer exposure.
Oligomer concentrations and time schedule exposure were de®ned in preliminary experiments. Cell proliferation was evaluated by measuring growth curves of cells seeded with or without ODN and IFN-a2a. Duplicate samples were counted at dierent times; cell viability was controlled by trypan blue exclusion. Cell growth was expressed as percentage relative to untreated controls. Experiments were repeated three times.
In parallel to cell proliferation, c-myc expression was analysed by immunoblotting, in corresponding cell lysates. 
